Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LM-102 |
| Synonyms | |
| Therapy Description |
LM-102 is a monoclonal antibody that targets CLDN18.2, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary) |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LM-102 | LM102|LM 102 | CLDN18.2 Antibody 23 | LM-102 is a monoclonal antibody that targets CLDN18.2, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary) |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04735796 | Phase I | LM-102 | Study of LM-102 in Subjects in Advanced Tumors | Terminated | USA | 0 |